The purpose of this funding opportunity announcement (FOA) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development.
- Letter of Intent Due Date(s): January 14, 2022; January 12, 2024
- Application Due Date(s): February 15, 2022; February 13, 2024
RFA-FD-22-001 Expiration Date February 14, 2024